Now showing items 1-2 of 2

    • Ceftazidime-avibactam to treat life-threatening infections by carbapenem-resistant pathogens in critically ill mechanically ventilated patients 

      Tsolaki V., Mantzarlis K., Mpakalis A., Malli E., Tsimpoukas F., Tsirogianni A., Papagiannitsis C., Zygoulis P., Papadonta M.-E., Petinaki E., Makris D., Zakynthinos E. (2020)
      Data on the effectiveness of ceftazidime-avibactam (CAZ-AVI) in critically ill, mechanically ventilated patients are limited. The present retrospective observational cohort study, which was conducted in two general intensive ...
    • Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study 

      Harris P.N.A., Pezzani M.D., Gutiérrez-Gutiérrez B., Viale P., Hsueh P.-R., Ruiz-Garbajosa P., Venditti M., Tumbarello M., Navarro-Francisco C., Calbo E., Akova M., Giamarellou H., Oliver A., Almirante B., Gasch O., Martínez-Martínez L., Schwaber M.J., Daikos G., Pitout J., Peña C., Hernández-Torres A., Doi Y., Pérez F., Tuon F.F., Tacconelli E., Carmeli Y., Bonomo R.A., Pascual Á., Paterson D.L., Rodríguez-Baño J., del Toro M.D., Gálvez J., Falcone M., Russo A., Karaiskos I., Trecarichi E.M., Losito A.R., García-Vázquez E., Gómez J., Roilides E., Iosifidis E., Pournaras S., Prim N., Navarro F., Mirelis B., Origüen J., Juan R.S., Fernández-Ruiz M., Almela M., de la Calle C., Martínez J.A., Morata L., Larrosa N., Puig-Asensio M., Bou G., Molina J., González V., Bermejo J., Rucci V., de Gopegui E.R., Marinescu C.I., Fariñas M.C., Cano M.E., Gozalo M., Paño-Pardo J.R., Mora-Rillo M., Gómez-Zorrilla S., Tubau F., Tsakris A., Zarkotou O., Antoniadou A., Poulakou G., Souli M., Lowman W., Virmani D., Torre-Cisneros J., Machuca I., Gracia-Ahufinger I., Azap Ö.K., Helvaci Ö., Sahin A.O., Cantón R., Pintado V., Bartoletti M., Giannella M., Peter S., Hamprecht A., Badia C., Xercavins M., Fontanals D., Jové E., ESGBIS/REIPI/INCREMENT Group (2017)
      We describe regional differences in therapy for bloodstream infection (BSI) caused by extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) or carbapenemase-producing Enterobacteriaceae (CPE). Patients (n = ...